Article Text

other Versions

PDF

Letter
Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies
  1. Giulia Berzero1,2,
  2. Evgenia Karantoni1,
  3. Caroline Dehais1,
  4. François Ducray3,
  5. Laure Thomas3,
  6. Géraldine Picard3,
  7. Véronique Rogemond3,
  8. Gaëlle Candelier1,
  9. Jean-Philippe Camdessanché4,5,6,
  10. Jean-Christophe Antoine4,6,5,
  11. Jérôme De Seze7,
  12. Amélie Liou-Schischmanoff8,
  13. Jérôme Honnorat3,6,5,
  14. Jean-Yves Delattre1,9,
  15. Dimitri Psimaras1
  1. 1Service de Neurologie 2-Mazarin, AP-HP Groupe Hospitalier Pitié-Salpêtrière, Paris, France
  2. 2Neuroscience Consortium, University of Pavia, Monza Policlinico, and Pavia Mondino, Italy
  3. 3Centre de Référence National pour les Syndromes Neurologiques Paranéoplasiques, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Lyon, France
  4. 4Service de Neurologie, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France
  5. 5Université Claude Bernard Lyon 1, F-69372, Université de Lyon, Lyon, France
  6. 6Institut NeuroMyoGene, INSERMU1217/CNRS UMR 5310, Lyon, France
  7. 7Service de Neurologie, Hôpital Civil, Strasbourg, France
  8. 8Service Pharmacie, Pôle SPEPS, Hôpitaux Universitaires Pitié Salpetrière–Charles Foix, Paris, France
  9. 9Centre de Recherche de l’Institut du Cerveau et de la Moelle Epinière (CRICM), UMRS 975, Université Pierre et Marie Curie - Paris VI, Paris, France
  1. Correspondence to Dr Dimitri Psimaras, Service de Neurologie 2-Mazarin, AP-HP Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l’Hôpital, Paris 75013, France; dimitri.psimaras{at}aphp.fr

Statistics from Altmetric.com

Introduction

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer, characterised by relentless progression. The mainstay of PNS treatment is the achievement of tumour remission,1 while immunotherapy provides only little additional benefit.2 3 However, in historical series, immunotherapy was initiated over 6 months after neurological onset and, at that stage, neuronal loss is already extensive and irreversible.

Among available immunotherapies, intravenous immunoglobulin (IVIg) has been used in single cases4 and in one retrospective series,3 showing some efficacy when administered timely.4 Based on these findings, we designed a prospective study to assess the efficacy and safety of early IVIg treatment in patients with PNS.

Methods

Study design

This prospective, multicentre, non-comparative, phase II clinical study was performed by the ‘Centre de Reference Français des Syndromes Neurologiques Paranéoplasiques’. Written informed consent was obtained from all participants. This trial is registered at ClinicalTrials.gov (NCT02343211). 

Participants

Inclusion criteria were: (1) diagnosis of ‘definite’ PNS5; (2) anti-Hu, anti-Yo, or anti-CV2/CRMP5 antibodies in the serum and/or in the cerebrospinal fluid; (3) neurological symptom onset within 6 months; (4) modified Rankin Score (mRS) 2 or 3; (5) neurological deterioration over the last 3 weeks. Exclusion criteria were: (1) other concomitant immunotherapy; (2) absolute contraindications to IVIg (hypersensitivity to IVIg, selective IgA deficiency); (3) thrombophilia; (4) renal insufficiency (creatinine clearance <30 mL/min).

Interventions

Enrolled patients received three cycles of IVIg (Privigen, 2 g/kg, every 4 weeks), followed by an interim evaluation. If the patient was stable or improved according to the primary outcome measure, three additional IVIg cycles were administered. If the patient deteriorated, IVIg was discontinued. Final evaluation was performed at 6 months.

The primary endpoint was improvement on the mRS at 3 months (decrease of at least one point). Secondary endpoints were: improvement on the mRS at 6 months (decrease of at least one point), improvement on the International Cooperative Ataxia Rating Scale (ICARS) at 3 and 6 months in patients with cerebellar ataxia (decrease of at least 10 points) and improvement on the Overall Neuropathy Limitations Scale (ONLS) at 3 and 6 months in patients with peripheral neuropathy (decrease of at least one point).

Adverse events were classified according to the Common Terminology Criteria for Adverse Events (CTCAE) V.4.03.

In patients without a history of cancer, a search for an occult neoplasm was performed. Whenever indicated, tumour treatment was started promptly (according to the schedule established by the referring oncologist) and was performed in parallel with IVIg treatment.

Post hoc analyses

Patients continued to be followed after the end of the 6-month study period, as part of the normal follow-up for their disease. Survival analyses were performed by the Kaplan-Meier method.

Results

Patient characteristics

The clinical features of the 17 patients are reported in table 1. Fourteen patients had anti-Hu, two patients had anti-CV2/CRMP5 and one patient had anti-Yo antibodies. Three patients had isolated central nervous system involvement, three patients had mixed central and peripheral impairment, while 11 patients had isolated peripheral neuropathies. In all patients, cerebrospinal fluid analysis showed inflammatory abnormalities. Thirteen patients had an associated cancer, 11 of whom received anti-tumour treatments in parallel with IVIg.

Table 1

Clinical characteristics of the 17 patients included in the present study

IVIg treatment

Median delay between neurological symptom onset and the start of IVIg treatment was 3 months (range 1–5.5). The median number of IVIg cycles per patient was 5.

Neurological outcome

Primary endpoint

Of the 17 patients enrolled, 13 patients were evaluable at 3 months. The primary endpoint (improvement of the mRS at 3 months) was reached by two patients (12%) (patients 1 and 3). The expected threshold to consider the treatment effective (five patients) was not reached. Nine patients had a stable mRS (53%) and remained ambulatory, while two patients deteriorated on the mRS (12%) (patients 2 and 4).

Secondary endpoints

Twelve patients were evaluable at 6 months. At this time point, and compared with baseline mRS, two patients had improved (12%), six patients were stable (35%) and four patients had deteriorated (24%).

Scores on the neurological scales ONLS and ICARS were analysed. The ONLS showed improvement at 3 and 6 months in two patients (patients 7, 17) who were stable according to the mRS. The ONLS also showed deterioration at 6 months in one patient (patient 10) who was stable on the mRS. The ICARS was administered to a single patient with cerebellar degeneration (patient 9), showing a consistent improvement which, however, did not exceed the established threshold. Online supplementary figure 1 summarises the results from primary and secondary outcome measures.

Supplementary figure 1

Neurological outcome at3 (panel A) and at 6 (panel B) months. Histograms show the number of patients who improved, were stable or deteriorated on the modified Rankin Score (orange)and on specific neurological grading scales (Overall Neuropathy Limitation Scale or International Cooperative Ataxia Rating Scale) (purple) at the different time points. *Patients with isolated limbicencephalitis were evaluated with the modified Rankin Score, as no neurological grading scale for cognitive impairment was provided.

Safety and tolerability

Four patients (24%) experienced grade 3 or 4 CTCAE: one patient had an allergic reaction (patient 6), one patient had a catheter infection (patient 10) and two patients developed sepsis (patients 12 and 15). Patient 12 died from sepsis. In the remaining three cases, the adverse event completely resolved with appropriate treatment.

Mortality

Five patients died during the 6-month study period (patients 6, 11–14). Cause of death was tumour progression (two patients), PNS (one patient), sepsis (one patient) and fall with head trauma (one patient).

Post hoc analyses

Patients were followed for a median follow-up of 13.7 months from enrolment (range 2.3–40.9). During the extension period, four additional patients died due to cancer progression (patients 5, 7, 9, 10). The median survival time in our cohort was 25.6 months.

Discussion

This study is the first prospective trial that assesses the efficacy of IVIg treatment in patients with PNS. The goal of the study was to start immunotherapy as early as possible, at a stage where inflammation is prominent. This enrolment goal was achieved, as half of our patients were enrolled within 3 months of neurological symptom onset. Enrolment was restricted to ambulatory patients, as preserved ambulation was considered an encouraging feature. At 3 months from enrolment, most of our patients had improved (12%) or stabilised (53%) on the mRS, remaining ambulatory.

In order to be consistent with other PNS trials, we chose the mRS as the primary outcome measure. However, we observed that neurological grading scales captured minor improvements or deteriorations more accurately than the mRS. Future studies should consider using neurological grading scales as primary outcome measures.

Patients in whom a tumour was present received antitumour treatment in parallel with IVIg. Although tumour treatment could indeed have contributed to therapeutic results, neurological improvement was also detected in patients who did not receive concomitant tumour treatment (patients 1, 3, 9, 17), suggesting a beneficial independent effect of IVIg.

Four patients had a severe adverse event, which was ultimately fatal in one case (sepsis). Sepsis is a recognised cause for hospitalisation and death in cancer patients, and therefore it is impossible to distinguish the role of IVIg treatment in causing this complication.

In the present series, median overall survival time was 25.6 months, highlighting the recent dramatic increase in patient survival.2 3 Unlike in other reports,2 only one death in our study was directly attributable to the neurological disorder. These data support the view that immunotherapy should be administered as soon as possible, in order to stabilise the patient at an ambulatory status and prevent the life-threatening complications related to severe neurological disability.

References

View Abstract

Footnotes

  • GB and EK contributed equally.

  • Contributors GB: data collection, analysis and interpretation of the data, manuscript drafting and revision. EK: study design, analysis and interpretation of the data, manuscript revision. CD, FD, LT, GP, J-PC, J-CA, JDS: analysis and interpretation of the data, manuscript revision. VR: data collection, manuscript revision. GC: data collection, manuscript revision. ALS: study design, data collection. JH and DP: study design, data collection, analysis and interpretation of the data, manuscript revision. J-YD: study design, analysis and interpretation of the data, manuscript revision.

  • Funding This investigator-led study was funded by a grant from CSL Behring through The Interlaken Leadership Awards (2011). Study design, data analysis and reporting were entirely performed by the investigators. The French Reference Center for Paraneoplastic Neurological Syndromes receives support from CSL Behring for the national database on paraneoplastic neurological syndromes and autoimmune encephalitis.

  • Competing interests JH received speaker honoraria from CSL Behring.

  • Ethics approval Institutional Ethics Committee of Groupe Hospitalier Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.